Christopher P. Austin, MD
National Center for Advancing Translational Sciences
Christopher P. Austin, M.D., is director of the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH). Austin leads the Center’s work to improve the translation of observations in the laboratory, clinic and community into interventions that reach and benefit patients—from diagnostics and therapeutics to medical procedures and behavioral changes. Under his direction, NCATS researchers and collaborators are developing new technologies, resources and collaborative research models; demonstrating their usefulness; and disseminating the data, analysis and methodologies for use by the worldwide research community.
Austin’s career has spanned the spectrum of translational research, in the public and private sectors. Austin joined NIH in 2002 as the senior advisor to the director for translational research at the National Human Genome Research Institute, where he was responsible for conceptualizing and implementing research programs to derive scientific insights and therapeutic benefit from the newly completed Human Genome Project. While at NHGRI, he founded and directed the NIH Chemical Genomics Center, Therapeutics for Rare and Neglected Diseases program, Toxicology in the 21st Century initiative, and NIH Center for Translational Therapeutics. Upon creation of NCATS in 2011, he became the inaugural director of the NCATS Division of Pre-Clinical Innovation, and was appointed NCATS director in 2012. Prior to joining NIH, Austin worked at the pharmaceutical company Merck, where he directed programs on genome-based discovery of novel targets and drugs, with a particular focus on schizophrenia and Alzheimer’s disease.
Austin is trained as a clinician and geneticist. He trained in internal medicine and neurology at the Massachusetts General Hospital in Boston, and practiced medicine in academic and community hospital settings as well as in urban primary care and in rural Alaska and Africa. He completed a research fellowship in developmental neurogenetics at Harvard, studying genetic and environmental influences on stem cell fate determination. Austin earned an M.D. from Harvard Medical School and A.B.summa cum laude in biology from Princeton University.
Michael Rosenblatt, MD
Executive Vice President and Chief Medical Officer
Merck & Co. Inc.
Scientist, educator, hospital and global healthcare company executive, Michael Rosenblatt, M.D., is executive vice president and chief medical officer at Merck. He is the company’s primary external advocate on medical issues and represents the voice of the patient inside Merck.
Dr. Rosenblatt previously was Dean of Tufts University School of Medicine; the George R. Minot Professor of Medicine at Harvard Medical School; and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology.
Prior to these leadership positions, he was senior vice president for research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®). Earlier, he was chief of the Endocrine Unit at the Massachusetts General Hospital.
Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies and is a scientific founder of ProScript, Radius Pharmaceuticals and Theracrine.
Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.
He received his undergraduate degreesumma cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School.